-
1.
公开(公告)号:US20200329684A1
公开(公告)日:2020-10-22
申请号:US16846718
申请日:2020-04-13
发明人: Takashi Okada , Tsutomu Igarashi , Asaka Shiozawa
IPC分类号: A01K67/027
摘要: Retinal detachment sometimes occurs during the aging process of retinal degeneration 6 model mouse (rd6 model mouse). The present invention provides a method for obtaining a retinal degeneration (rd) model mouse having a low risk of causing retinal detachment, including: acquiring tissue data about a retinal tissue in an rd model mouse by using a retinal examination means; determining whether or not the tissue data meets an evaluation criterion; and selecting the rd model mouse, the tissue data of which meets the evaluation criterion.
-
公开(公告)号:US11845952B2
公开(公告)日:2023-12-19
申请号:US16968397
申请日:2019-01-16
发明人: Takashi Okada , Tsutomu Igarashi , Asaka Shiozawa
IPC分类号: C12N15/861 , A61P27/02 , A61K35/761 , A61K38/18 , A61K39/235
CPC分类号: C12N15/861 , A61K35/761 , A61K38/1833 , A61K39/235 , A61P27/02
摘要: One disadvantage of adeno-associated virus (AAV) is low gene expression efficiency due to delayed expression of the inserted gene. Provided is a vector plasmid for producing a vector genome to be inserted into an adeno-associated virus (AAV). The vector plasmid is provided with a vector genome cassette as a template of the vector genome, and the vector genome cassette is provided with: (1) an expression cassette including a nucleic acid molecule encoding a target gene and (b) a nucleic acid molecule encoding an expression regulatory region that allows expression of the target gene; and (2) two nucleic acid molecules positioned on both sides of the expression cassette and encoding inverted terminal repeats (ITRs). Also provided is a pharmaceutical composition containing the AVV vector, for treating or preventing an eye disease or disease associated with same. Further provided is a method for treating or preventing the eye disease or disease associated with same, comprising administering a therapeutically effective amount of the pharmaceutical composition for treating or preventing the eye disease or disease associated with same to a subject suffering from the eye disease or disease associated with same.
-
公开(公告)号:US11028131B2
公开(公告)日:2021-06-08
申请号:US16481159
申请日:2018-01-29
申请人: NIPPON MEDICAL SCHOOL FOUNDATION , NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY , TAKARA BIO INC.
发明人: Takashi Okada , Hironori Okada , Hiromi Kinoh , Tatsuji Enoki , Toshikazu Nishie , Junichi Mineno
IPC分类号: C12N7/00 , C12N15/00 , C07K14/005 , C12N15/85
摘要: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
-
公开(公告)号:US20220127606A1
公开(公告)日:2022-04-28
申请号:US17310239
申请日:2020-01-29
发明人: Takashi Okada , Hiromi KINOH , Yoshitsugu AOKI , Shin'ichi TAKEDA
IPC分类号: C12N15/113 , A61P21/04 , A61K47/64 , A61K9/10 , A61K9/14
摘要: Provided are a complex that comprises a nucleic acid-containing nanoparticle and a hollow particle of a non-enveloped virus, a method for producing the complex, and a pharmaceutical composition comprising the complex.
-
公开(公告)号:US20210087560A1
公开(公告)日:2021-03-25
申请号:US16967483
申请日:2019-02-06
申请人: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY , NIPPON MEDICAL SCHOOL FOUNDATION , DAIICHI SANKYO COMPANY, LIMITED
发明人: Ken Inoue , Heng Li , Takashi Okada , Yu Ohki , Makoto Koizumi
IPC分类号: C12N15/113 , C12N15/86
摘要: An object of the present invention is to provide a vector capable of oligodendrocyte-specifically suppressing expression of the PLP1 gene for treating PMD caused by abnormality of the PLP1 gene, and a promoter and miRNA therefor, and a pharmaceutical composition comprising the vector. The oligodendrocyte-specific promoter of the present invention comprises a nucleic acid having a sequence identity of at least 90% to a nucleotide sequence set forth in SEQ ID NO: 1. The miRNA of the present invention specific to the PLP1 gene comprises a pair of nucleotide sequences consisting of a specific antisense sequence and sense sequence.
-
-
-
-